| 51 |
28345838 | ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy | 2017 Feb 1 |
3 |
| 52 |
28361849 | Effect of antitumor drugs in low concentrationson the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro. | 2017 Mar |
1 |
| 53 |
28422153 | Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. | 2017 Apr 19 |
1 |
| 54 |
28535002 | hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. | 2017 Jul |
1 |
| 55 |
28659181 | Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy. | 2017 Jun 28 |
1 |
| 56 |
29156754 | Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer. | 2017 Oct 17 |
2 |
| 57 |
26870207 | Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study. | 2016 Jan |
4 |
| 58 |
27453264 | Lanthanum chloride enhances cisplatin-induced apoptosis in ovarian cancer cells. | 2016 Jun 30 |
1 |
| 59 |
27473273 | The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. | 2016 Dec |
1 |
| 60 |
27501338 | Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. | 2016 Sep |
2 |
| 61 |
27514406 | Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner. | 2016 Nov |
4 |
| 62 |
27610644 | Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors. | 2016 Dec |
3 |
| 63 |
27650543 | Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. | 2016 Nov 15 |
5 |
| 64 |
27721259 | Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. | 2016 Oct |
4 |
| 65 |
28105156 | Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma. | 2016 Dec |
2 |
| 66 |
25434755 | Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer. | 2015 Feb |
4 |
| 67 |
25650716 | Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. | 2015 |
1 |
| 68 |
25857670 | The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis. | 2015 Jun |
4 |
| 69 |
25941922 | Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. | 2015 Jul |
9 |
| 70 |
25944617 | The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. | 2015 Aug 7 |
6 |
| 71 |
25946469 | Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. | 2015 Aug 15 |
1 |
| 72 |
25956741 | Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance. | 2015 Jul |
1 |
| 73 |
25989663 | [Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma]. | 2015 Jan |
3 |
| 74 |
26045829 | Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer. | 2015 |
1 |
| 75 |
26066774 | Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation. | 2015 |
2 |
| 76 |
26125934 | Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. | 2015 Jun 29 |
3 |
| 77 |
26137163 | Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. | 2015 Jun |
2 |
| 78 |
26162296 | ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. | 2015 Nov |
1 |
| 79 |
26165688 | Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens. | 2015 Jul 22 |
1 |
| 80 |
26200905 | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. | 2015 |
1 |
| 81 |
26313152 | IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. | 2015 Sep 29 |
1 |
| 82 |
26345951 | Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma. | 2015 Aug 21 |
1 |
| 83 |
26384430 | CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. | 2015 Dec 15 |
3 |
| 84 |
26400354 | Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. | 2015 Sep 22 |
2 |
| 85 |
26557761 | ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. | 2015 |
2 |
| 86 |
26882613 | [Effect of Peimine on ERCC1 mRNA and LRP Expressions of A549/DDP Multidrug Resistance Cell Line]. | 2015 Dec |
1 |
| 87 |
26905109 | Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy? | 2015 Jul-Sep |
3 |
| 88 |
24158589 | Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer. | 2014 Feb |
1 |
| 89 |
24403450 | ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. | 2014 Jan |
10 |
| 90 |
24403494 | ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. | 2014 Jan |
1 |
| 91 |
24403499 | Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. | 2014 Jan |
2 |
| 92 |
24638013 | Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. | 2014 Apr 20 |
2 |
| 93 |
24699918 | ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. | 2014 Jun |
3 |
| 94 |
24799992 | Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. | 2014 Apr 27 |
2 |
| 95 |
24817012 | Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. | 2014 Aug |
1 |
| 96 |
24935625 | Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. | 2014 Jul |
3 |
| 97 |
25076246 | Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy. | 2014 May-Jun |
3 |
| 98 |
25083297 | Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. | 2014 Aug |
5 |
| 99 |
25191856 | ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China. | 2014 |
2 |
| 100 |
25217323 | ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer. | 2014 Dec |
5 |